Insights

Immunotherapy Portfolio Cullinan Therapeutics has a diversified portfolio of clinical-stage assets in oncology and autoimmune diseases, focusing on inhibiting disease drivers and utilizing the immune system. This portfolio presents an opportunity for sales professionals to explore collaborations and partnerships in advancing transformative therapeutics.

Investment Partnership Quest Partners LLC recently invested $179,000 in Cullinan Therapeutics. This investment signifies external confidence in the company's potential, opening avenues for sales representatives to leverage this endorsement in building investor relations and potential future funding rounds.

T-Cell-Engager Therapy Cullinan Therapeutics is exclusively developing CLN-978, a T-cell-engager, as a treatment for autoimmune disorders, starting with systemic lupus erythematosus. Sales development professionals can explore collaborations with the company for promoting this innovative therapy in the market and expanding its reach to a wider patient base.

Financial Leadership Mary Kay Fenton joined Cullinan Therapeutics as the Chief Financial Officer, bringing expertise in financial management to the company. Sales representatives can capitalize on this leadership addition to showcase the financial stability and strategic planning capabilities of the company to potential clients and stakeholders.

Revenue Potential With a revenue ranging between $10M - $50M, Cullinan Therapeutics demonstrates sound financial health within its industry. Sales professionals can leverage this information to align with potential partners, investors, and clients who seek to collaborate with financially stable and growing biotechnology research companies.

Cullinan Therapeutics Tech Stack

Cullinan Therapeutics's Email Address Formats

Cullinan Therapeutics uses at least 2 format(s):
Cullinan Therapeutics Email FormatsExamplePercentage
last@cullinanoncology.comDoe@cullinanoncology.com
33%
flast@cullinanoncology.comJDoe@cullinanoncology.com
11%
firstlast@cullinanoncology.comJohnDoe@cullinanoncology.com
12%
first.last@cullinanoncology.comJohn.Doe@cullinanoncology.com
11%
f.last@cullinanoncology.comJ.Doe@cullinanoncology.com
11%
first@cullinanoncology.comJohn@cullinanoncology.com
11%
fmiddlelast@cullinanoncology.comJMichaelDoe@cullinanoncology.com
11%

Frequently Asked Questions

Where is Cullinan Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Cullinan Therapeutics's main headquarters is located at 1 Main St Cambridge, Massachusetts 02142 US. The company has employees across 2 continents, including North AmericaEurope.

What is Cullinan Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Cullinan Therapeutics is a publicly traded company; the company's stock symbol is CGEM.

What is Cullinan Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Cullinan Therapeutics's official website is cullinantherapeutics.com and has social profiles on LinkedIn.

How much revenue does Cullinan Therapeutics generate?

Minus sign iconPlus sign icon
As of May 2024, Cullinan Therapeutics's annual revenue reached $35M.

What is Cullinan Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Cullinan Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cullinan Therapeutics have currently?

Minus sign iconPlus sign icon
As of May 2024, Cullinan Therapeutics has approximately 94 employees across 2 continents, including North AmericaEurope. Key team members include Chief Scientific Officer: J. M.Chief Human Resources Officer: S. A.Chief Medical Officer: J. J.. Explore Cullinan Therapeutics's employee directory with LeadIQ.

What industry does Cullinan Therapeutics belong to?

Minus sign iconPlus sign icon
Cullinan Therapeutics operates in the Biotechnology Research industry.

What is Cullinan Therapeutics's email format?

Minus sign iconPlus sign icon
Cullinan Therapeutics's email format typically follows the pattern of . Find more Cullinan Therapeutics email formats with LeadIQ.
Cullinan Therapeutics

Cullinan Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Cullinan Therapeutics is dedicated to creating new standards of care for patients. 
 
We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class.  

Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.

Section iconCompany Overview

Headquarters
1 Main St Cambridge, Massachusetts 02142 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
CGEM
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $10M$50M

    Cullinan Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $10M$50M

    Cullinan Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.